Comparison of Acarbose and Gliclazide as First-line Agents in Patients with Type 2 Diabetes

References

• Lebovitz, H. E. (1994). Oral antidiabetic agents. In Kahn, C. R. and Weir G. C. (Eds), Joslin's Diabetes Mellitus. Lea & Febiger, Pennsylvania, 13th edn, 508–529.
   Google Scholar
• United Kingdom Prospective Diabetes Study Group (1995). The United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ, 14, 83–88.
   Google Scholar
• Marsiaj, H. I., Catalano, C., Sum, C. R, Home, P. D. and Alberti, K. G. (1991). Management of newly diagnosed non-insulin-dependent (Type 2) diabetes mellitus: A retrospective audit. Diabetes Res. Clin. Pract., 12, 129–136.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association (1999). Implications of the United Kingdom Prospective Diabetes Study. Annual Review of Diabetes, Carden Jennings, Virginia, pp. 68–74.
   Google Scholar
• The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997). Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care, 20, 1183–1197.
   PubMed Web of Science ®Google Scholar
• Chiasson, J. L., Gomis, R., Hanefeld, M., Josse, R. G., Karasik, A. and Laakso, M. (1998). The STOP-NIDDM Trial: An international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: Rationale, design, and preliminary screening data. Study to prevent non-insulin-dependent diabetes mellitus. Diabetes Care, 21, 1720–1725.
   PubMed Web of Science ®Google Scholar
• Holman, R. R. (1998). Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res. Clin. Pract., 40 (Suppl. 1), S21–S25.
   PubMedGoogle Scholar
• Li, C. L., Pan, C. Y., Lu, J. M., Zhu, Y., Wang, J. H., Deng, X. X., Xia, F. C., Wang, H. Z. and Wang, H. Y. (1999). Effect of metformin on patients with impaired glucose tolerance. Diabet. Med., 16, 477–481.
   PubMed Web of Science ®Google Scholar
• Chaisson, J. L., Josse, R., Hunt, J., Palmason, C., Rodger, W., Ross, S., Ryan, E. A., Tan, M. H. and Wolever, M. S. (1994). The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann. Intent Med., 121, 928–935.
   PubMed Web of Science ®Google Scholar
• Garcia de los Rios, M., Mujica, V., Munoz, S., Durruty, P., Larenas, G., Lopez, M. I., Kuzmanic, A., Perez, J., Flaskamp, R. and Cumsille, F. (1997). Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter Study. Rev. Med. Child, 125, 856–862.
   PubMedGoogle Scholar
• Hoffmann, J. (1994). Efficacy of 24 week monotheraphywithacarbose,glibenclamide, or placebo in NIDDM patients. The Essen study. Diabetes Care, 17, 561–566.
   PubMed Web of Science ®Google Scholar
• Seshiah, V., Venkataraman, S. and Suresh, K. (1993). Gliclazide in the treatment of obese non-insulin-dependent diabetic patients. J. Assoc. Phys. India, 41, 367–368.
   PubMedGoogle Scholar
• Chait, A. and Bierman, E. L. (1994). Pathogenesis of macrovascular disease in diabetes. In: Joslin's Diabetes Mellitus. Lea & Febiger, Pennsylvania, 13th edn, pp. 648–664.
   Google Scholar
• Balkau, B. and Esewege, E. (1999). Insulin resistance: An independent risk factor for cardiovascular disease? Diabetes Obes. Metab., 1 (Suppl. 1), S23–S31.
   PubMedGoogle Scholar
• Johnston, P. S., Lebovitz, H. E., Coniff, R., Simonson, D. C., Raskin, P. and Munera, C. (1998). Advantages of a-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J. Clin. Endocrinol. Metab., 83,1515–1522.
   Google Scholar
• Leonhardt, W., Hanefeld, M., Fisher, S. and Shulze, J. (1994). Efficacy of alpha-glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidemia. Eur. Clin. Invest., 24 (Suppl. 3), 45–49.
   PubMedGoogle Scholar
• Kado, S., Murakami, T., Aoki, A., Nagase, T., Katsura, Y., Noritake, M., Matsuoka, T. and Nagata, N. (1998). Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res. Clin. Pract., 41, 49–55.
   PubMed Web of Science ®Google Scholar
• Hanefeld, M. and Julius, U. (1995). Oral hypoglycaemics. In Hanefeld, M. B. (Ed.), A Practical Guide to the Therapy of Type II Diabetes. de Gruyter, New York, pp. 130-137.
   Google Scholar
• Hollander, P. (1992). Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs, 44 (Suppl 3), 47–53.
   PubMedGoogle Scholar
• Van Gaal, L., Nobels, F. and De Leeuw I. (1991). Effects of acarbose on carbohydrate metabolism, electrolytes, minerals and vitamins in fairly well-controlled non-insulin-dependent diabetes mellitus. Z. Gastroenterol., 29, 642–644.
   Google Scholar
• Couet, C., Ulmer, M., Hamdaoui, M., Bau, H. M. and Debry, G. (1989). Metabolic effects of acarbose in young healthy men. Eur. J. Clin. Nutr., 43, 187–196.
   PubMed Web of Science ®Google Scholar
• Chan, J. C., Chan, K. W., Ho, L. L., Fuh, M. M., Horn, L. C., Sheaves, R., Panelo, A. A., Kim, D. K., Embong, M. and the Asian Acarbose Study Group (1998). An Asian multicenter clinical trial to assess the efficacy and tolerability of acarbose compared with placebo in type 2 diabetic patients previously treated with diet. Diabetes Care, 21, 1058–1061.
   PubMed Web of Science ®Google Scholar
• Wolever, T. M., Chiasson, J. L., Josse, R. G., Hunt, J. A., Palmason, C., Rodger, N. W., Ross, S. A., Ryan, E. A. and Tan, M. H. (1998). No relationship between carbohydrate intake and effect of acarbose on HbAlc or gastrointestinal symptoms in type 2 diabetic subjects consuming 30-60% of energy from carbohydrate. Diabetes Care, 21, 1612–1618.
   PubMed Web of Science ®Google Scholar
• Hoffmann, J. and Spengler, M. (1997). Efficacy of 24 week monotheraphy with acarbose, metformin or placebo in dietary-treated NIDDM patients: The Essen-II study. Am. J. Med., 103, 483–490.
   PubMed Web of Science ®Google Scholar